Dashenlin Pharm Grp Co Ltd (603233) - Total Liabilities
Based on the latest financial reports, Dashenlin Pharm Grp Co Ltd (603233) has total liabilities worth CN¥17.65 Billion CNY (≈ $2.58 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Dashenlin Pharm Grp Co Ltd growing its equity to track the company's year-over-year net asset growth rate.
Dashenlin Pharm Grp Co Ltd - Total Liabilities Trend (2012–2025)
This chart illustrates how Dashenlin Pharm Grp Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Dashenlin Pharm Grp Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Dashenlin Pharm Grp Co Ltd Competitors by Total Liabilities
The table below lists competitors of Dashenlin Pharm Grp Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
India | Rs10.56 Billion |
|
Shanghai V-Test Semiconductor Tech Co. Ltd. A
SHG:688372
|
China | CN¥4.57 Billion |
|
Piramal Pharma Limited
NSE:PPLPHARMA
|
India | Rs98.02 Billion |
|
SL Green Realty Corp
NYSE:SLG
|
USA | $6.73 Billion |
|
Elmos Semiconductor SE
F:ELG
|
Germany | €204.27 Million |
|
Zhejiang Huazheng New Material
SHG:603186
|
China | CN¥4.29 Billion |
|
Fortuna Silver Mines Inc
TO:FVI
|
Canada | CA$569.64 Million |
|
Procter & Gamble Hygiene and Health Care Limited
NSE:PGHH
|
India | Rs10.50 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Dashenlin Pharm Grp Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Dashenlin Pharm Grp Co Ltd market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.66 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dashenlin Pharm Grp Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dashenlin Pharm Grp Co Ltd (2012–2025)
The table below shows the annual total liabilities of Dashenlin Pharm Grp Co Ltd from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥17.83 Billion ≈ $2.61 Billion |
-2.60% |
| 2024-12-31 | CN¥18.30 Billion ≈ $2.68 Billion |
+13.04% |
| 2023-12-31 | CN¥16.19 Billion ≈ $2.37 Billion |
+15.83% |
| 2022-12-31 | CN¥13.98 Billion ≈ $2.05 Billion |
+22.61% |
| 2021-12-31 | CN¥11.40 Billion ≈ $1.67 Billion |
+68.66% |
| 2020-12-31 | CN¥6.76 Billion ≈ $989.06 Million |
+55.73% |
| 2019-12-31 | CN¥4.34 Billion ≈ $635.11 Million |
+25.79% |
| 2018-12-31 | CN¥3.45 Billion ≈ $504.89 Million |
+14.25% |
| 2017-12-31 | CN¥3.02 Billion ≈ $441.93 Million |
+34.94% |
| 2016-12-31 | CN¥2.24 Billion ≈ $327.50 Million |
+36.70% |
| 2015-12-31 | CN¥1.64 Billion ≈ $239.58 Million |
-8.55% |
| 2014-12-31 | CN¥1.79 Billion ≈ $261.98 Million |
+64.11% |
| 2013-12-31 | CN¥1.09 Billion ≈ $159.64 Million |
+77.27% |
| 2012-12-31 | CN¥615.39 Million ≈ $90.05 Million |
-- |
About Dashenlin Pharm Grp Co Ltd
DaShenLin Pharmaceutical Group Co., Ltd. manufactures, distributes, and retails pharmaceutical products in China. It offers Chinese and Western patent medicines, ginseng and antler tonic medicinal materials, Chinese herbal medicine slices, health products, medical devices, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.